Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The SMARTChip Stroke Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02795481
Recruitment Status : Recruiting
First Posted : June 10, 2016
Last Update Posted : October 18, 2018
Sponsor:
Information provided by (Responsible Party):
University Hospitals Coventry and Warwickshire NHS Trust

Brief Summary:

Stroke is one of the leading causes of death and disability in the UK and currently costs the country £7bn per year. There is an overwhelming need to accurately and rapidly triage patients to allow best use of finite NHS specialist resources for the treatment of stroke.

A simple blood test of substances (the purines) that result from cellular metabolism and are produced in excess when brain cells are starved of oxygen and glucose (as occurs during a stroke) is proposed. The sensors designed by the investigators are used to measure blood purines during a procedure in which blood flow to the brain is reduced to allow surgical interventions on the major arteries that supply the brain. Previous studies by the investigators have shown that as soon as blood flow to the brain is reduced, purines are produced within minutes and are detectable in systemic arterial blood.

The current project will now compare the levels of purines in the blood of stroke patients and controls. The purines will be measured on admission to hospital and 24 hours later. The occurrence and magnitude of a stroke will be determined by an MRI scan given between 24 and 72hrs after admission. This study will establish whether purines are elevated in the blood of stroke patients on admission to hospital compared to healthy controls, and whether this correlates with the size of the stroke and damage to the brain.


Condition or disease
Stroke

Detailed Description:

Stroke patients will be prospectively recruited to the trial on admission to A&E. The patient will undergo normal clinical assessment and treatment for stroke. As soon after admission as possible, a finger-prick blood sample will be taken from the patient and the SMARTChip device will be used to measure the levels of purines in the sample. A medical history of factors relevant to the purine test will also be established. This will include factors such as any medications that might alter purine levels, a prior history of strokes, diabetes, a history (individual or family) of gout, and when they last had food. The patient will also be given a CT head scan as part of their normal treatment.

In sub-set of patients repeated blood samples (once per hour for 6 hours) will be taken to gain information on how purine levels may change in blood following a stroke. In all patients, the blood purines will be re-tested at 24h (±3h).

All patients will be offered the option of an MRI brain scan at 24-72h post-admission and recruitment will continue until 100 patients with MRI measurements have been enrolled. The flexibility in the timing of the scan is to allow scheduling of the scan to fit in with other demands on the MRI. The purpose of the scan is to identify the nature of the cerebrovascular event and quantify any infarction or area of brain bleeding.

Control participants will give blood on 2 occasions 24h apart for a purine test. The purpose of this control is two-fold: 1) to establish the variability of blood purines in healthy controls and 2) to test whether stroke patients have elevated blood purine levels compared to healthy controls.

Healthy volunteer feeding controls will give a baseline blood sample, eat a simple purine rich meal (a meat sandwich) and then give 4 more blood samples at 10, 30, 60 and 120 minutes following the meal. The purpose of this control is to test whether ingestion of a recent meal might alter baseline blood purine measurements.

Main study patients recruited at University Hospitals North Midlands NHS Trust will also be given the option of participating in the Spasticity and Pharmacokinetic sub-studies. Participants taking part in the Spasticity sub-study will provide an additional blood sample to measure biomarkers and will undergo a spasticity assessment at admission, 24h, 72h, 7d and one or two clinic visits between 30-90d post-admission. Participants taking part in the pharmacokinetic sub-group will provide an additional blood sample for measurement of glutamate and other biomarkers at admission, 24h, 72h, 7d and 30-90d post-admission.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 375 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: SMARTChip: A Field Deployable Blood Test for Stroke, Capable of Detecting Brain Ischaemia From the Earliest Stages of Pathology
Study Start Date : July 2016
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019

Group/Cohort
Stroke patients
Adult stroke patients with suspected stroke will be recruited on admission to hospital. Recruitment will continue until 100 patients have received an MRI at 24h-72h post admission, up to a maximum recruitment threshold of 300 patients.
Control patients
50 adult control patients will be recruited from the non-vascular, non-oncological surgical lists at each participating site
Feeding control participants
15 healthy adult members of NHS staff will be recruited to participate in the feeding control sub-study at University Hospitals Coventry and Warwickshire NHS Trust only.
Spasticity sub-group controls
10 healthy adult members of NHS staff at University Hospitals of North Midlands, will be recruited to take part as spasticity sub-study controls
Traumatic brain injury patients
10 adult patients with an isolated traumatic brain injury at University Hospitals Coventry and Warwickshire NHS Trust and Imperial College Healthcare NHS Trust.



Primary Outcome Measures :
  1. To determine whether blood purine levels in stroke patients at admission correlate with infarct/ haemorrhage size as determined by MRI or CT scan at 24-72 hours after onset of symptoms [ Time Frame: 24-72h after onset of symptoms ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Stroke patients: adult patients admitted to the hospital experiencing symptoms of stroke at the time of admission

Controls: adult patients scheduled to undergo non-vascular, non-oncological surgery at the participating hospital sites

Feeding control and spasticity sub-study control participants: Healthy adult members of NHS staff

Traumatic brain injury sub-study: Adult patients with an isolated traumatic brain injury.

Criteria

Main study

Stroke patients:

Inclusion criteria:

  • Aged 18 years or over
  • Admitted to hospital with suspected stroke, diagnosed by a suitably qualified doctor or nurse using an appropriate clinical assessment (e.g. FAST, NIHSS, WHO criteria)
  • Patient has ongoing symptoms of stroke at the time of enrolment in to the study.

Exclusion criteria:

  • Onset of stroke symptoms >4.5 hours prior to admission or time of onset of symptoms is not known
  • Patient has undergone thrombolysis during current admission (N.B. patients can be enrolled before planned thrombolysis, but not after)
  • Patient's stroke symptoms have resolved completely prior to enrolment in the study
  • The patient, or their consultee if the patient is incapacitated, is unwilling to provide written informed consent

Healthy controls

Inclusion criteria:

  • Aged 18 years and over
  • Scheduled for surgery
  • Available for follow-up

Exclusion criteria:

  • History of, or evidence of current, cerebrovascular disease, including stroke, transient ischaemic attack, subarachnoid haemorrhage and vascular dementia
  • History of cardiovascular disease, including myocardial infarction, angina or peripheral vascular disease
  • History of, or current, gout
  • Currently receiving chemotherapy
  • History of diabetes
  • Unwilling or unable to provide written informed consent

Feeding Controls sub-study Inclusion criteria

  • Aged 18 years and over
  • Member of NHS staff
  • Willing to eat the study meal provided (sandwich with a meat based filling)

Exclusion criteria

  • Current acute health problems requiring medical review, investigation, or treatment
  • History of, or evidence of current, cerebrovascular disease, including stroke, transient ischaemic attack, subarachnoid haemorrhage and vascular dementia
  • History of cardiovascular disease, including myocardial infarction, angina or peripheral vascular disease
  • History of, or current, gout
  • Currently receiving chemotherapy
  • History of diabetes
  • Unwilling or unable to provide written informed consent

Spasticity sub-study

Stroke patients Inclusion criteria - Patients with suspected stroke, who have been enrolled on to the main study at UHNM

Exclusion criteria

- Unwilling or unable to provide written informed consent to the spasticity sub-study

Controls Inclusion criteria

  • Aged 18 years and over
  • Member of NHS staff
  • Willing to complete follow-up visits

Exclusion criteria

  • Current acute health problems requiring medical review, investigation, or treatment
  • History of, or evidence of current, cerebrovascular disease, including stroke, transient ischaemic attack, subarachnoid haemorrhage and vascular dementia
  • History of cardiovascular disease, including myocardial infarction, angina or peripheral vascular disease
  • History of gout
  • Currently receiving chemotherapy
  • History of diabetes
  • Unwilling or unable to provide written informed consent

Traumatic brain injury sub-study

Inclusion criteria:

  • Aged 18 years or over
  • Admitted to hospital with Traumatic brain injury, diagnosed by a suitably qualified doctor with CT scan supporting evidence of a bleed and/or clot.

Exclusion criteria:

  • The patient, or their consultee if the patient is incapacitated, is unwilling to provide written informed consent
  • History of Cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02795481


Contacts
Layout table for location contacts
Contact: Shivam Joshi 02476 966907 Shivam.Joshi@uhcw.nhs.uk

Locations
Layout table for location information
United Kingdom
University Hospitals Coventry & Warwickshire NHS Trust Recruiting
Coventry, United Kingdom, CV2 2DX
Contact: Shivam Joshi    02476 966907    Shivam.Joshi@uhcw.nhs.uk   
Sponsors and Collaborators
University Hospitals Coventry and Warwickshire NHS Trust
Investigators
Layout table for investigator information
Principal Investigator: Christopher Imray, PhD University Hospitals Coventry and Warwickshire NHS Trust

Layout table for additonal information
Responsible Party: University Hospitals Coventry and Warwickshire NHS Trust
ClinicalTrials.gov Identifier: NCT02795481     History of Changes
Other Study ID Numbers: CI166115
First Posted: June 10, 2016    Key Record Dates
Last Update Posted: October 18, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Individual participant data will not be shared

Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases